Leerink Partnrs Forecasts Stronger Earnings for bluebird bio

bluebird bio, Inc. (NASDAQ:BLUE) – Analysts at Leerink Partnrs increased their Q4 2024 earnings per share estimates for bluebird bio in a research note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will post earnings of ($4.42) per share for the quarter, up from their previous estimate of ($4.47). The consensus estimate for bluebird bio’s current full-year earnings is ($27.17) per share. Leerink Partnrs also issued estimates for bluebird bio’s FY2025 earnings at ($6.42) EPS.

BLUE has been the topic of a number of other research reports. StockNews.com assumed coverage on shares of bluebird bio in a report on Friday, December 20th. They issued a “sell” rating on the stock. JPMorgan Chase & Co. cut shares of bluebird bio from a “neutral” rating to an “underweight” rating in a report on Friday, November 15th. Bank of America cut bluebird bio from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $60.00 to $10.00 in a research note on Friday, November 15th. Barclays lifted their target price on bluebird bio from $2.00 to $40.00 and gave the company an “overweight” rating in a research report on Tuesday, December 31st. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $80.00 price target on shares of bluebird bio in a research report on Friday, November 15th. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $49.14.

bluebird bio Stock Down 0.9 %

Shares of NASDAQ BLUE opened at $7.80 on Friday. The firm’s fifty day moving average is $8.17 and its 200 day moving average is $11.81. bluebird bio has a 52 week low of $5.80 and a 52 week high of $38.40. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37. The company has a market cap of $75.82 million, a price-to-earnings ratio of -0.21 and a beta of 0.68.

Institutional Investors Weigh In On bluebird bio

Institutional investors have recently added to or reduced their stakes in the business. Verition Fund Management LLC purchased a new position in shares of bluebird bio in the 3rd quarter valued at approximately $42,000. SG Americas Securities LLC increased its stake in bluebird bio by 152.4% during the 3rd quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 74,185 shares in the last quarter. Captrust Financial Advisors increased its stake in bluebird bio by 48.2% during the 3rd quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 77,293 shares in the last quarter. Barclays PLC raised its holdings in shares of bluebird bio by 273.7% in the third quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock worth $130,000 after buying an additional 184,605 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in shares of bluebird bio by 2,270.2% during the third quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock worth $193,000 after buying an additional 355,562 shares during the period. Institutional investors and hedge funds own 87.43% of the company’s stock.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.